Alexei Protopopov
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Alexei Protopopov has a total of 43 co-authors. Here are the top co-authors by number of shared publications:
A. N. Al-Amin
Karolinska Institute
1 shared publicationA. V. Zelenin
Engelhardt Institute of Molecular Biology
1 shared publication- Andrew Futreal
Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, USA
1 shared publication - Angela Hadjipanayis
Target, Disease and Systems Biology, Sanofi
1 shared publication - Angeliki Pantazi
Department of Genetics, Harvard Medical School, Division of Genetics, Brigham and Women’s Hospital, Boston, MA, USA
1 shared publication Bianca Amador
Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
1 shared publication
Latest Publications
- Open Access
- 11 February 2022
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 8 (6) , eabm2382
A functional genomic approach to actionable gene fusions for precision oncology
Fusion genes represent a class of attractive therapeutic targets. Thousands of fusion genes have been identified in patients with cancer, but the functional consequences and therapeutic implications of most of these remain largely unknown. Here, we develop a functional genomic approach that consists of efficient fusion reconstruction and sensitive cell viability and drug response assays. Applying this approach, we characterize ~100 fusion genes detected in patient samples of The Cancer Genome Atlas, revealing a notable fraction of low-frequency fusions with activating effects on tumor growth. Focusing on those in the RTK-RAS pathway, we identify a number of activating fusions that can markedly affect sensitivity to relevant drugs. Last, we propose an integrated, level-of-evidence classification system to prioritize gene fusions systematically. Our study reiterates the urgent clinical need to incorporate similar functional genomic approaches to characterize gene fusions, thereby maximizing the utility of gene fusions for precision oncology.
- 11 February 2022
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 8 (6) , eabm2382
Open AccessA functional genomic approach to actionable gene fusions for precision oncology
Fusion genes represent a class of attractive therapeutic targets. Thousands of fusion genes have been identified in patients with cancer, but the functional consequences and therapeutic implications of most of these remain largely unknown. Here, we develop a functional genomic approach that consists of efficient fusion reconstruction and sensitive cell viability and drug response assays. Applying this approach, we characterize ~100 fusion genes detected in patient samples of The Cancer Genome Atlas, revealing a notable fraction of low-frequency fusions with activating effects on tumor growth. Focusing on those in the RTK-RAS pathway, we identify a number of activating fusions that can markedly affect sensitivity to relevant drugs. Last, we propose an integrated, level-of-evidence classification system to prioritize gene fusions systematically. Our study reiterates the urgent clinical need to incorporate similar functional genomic approaches to characterize gene fusions, thereby maximizing the utility of gene fusions for precision oncology.
- 1 September 2000
- Published by Springer Nature in Chromosome Research
- Vol. 8 (6) , 560
Human NRG3 gene Map position 10q22-q23
- 1 September 2000
- Published by Springer Nature in Chromosome Research
- Vol. 8 (6) , 560
Human NRG3 gene Map position 10q22-q23